Overview

A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

Status:
Completed

Trial end date:
2020-04-27

Target enrollment:

Participant gender:

Summary

This is a randomized, double-blind, placebo-controlled, multicenter phase 3 trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) and best supportive care (BSC) compared to placebo and BSC in treatment of residual Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT).

Phase:

Phase 3

Details

Lead Sponsor:

Seagen Inc.
Seattle Genetics, Inc.

Collaborator:

Millennium Pharmaceuticals, Inc.

Treatments:

Antibodies
Antibodies, Monoclonal
Brentuximab Vedotin